The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiomic analysis on pretreatment MRI to predict response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter study.
 
Hui-Chuan Sun
Employment - Zhongshan Hospital, Fudan University
Honoraria - AstraZeneca; Bayer; BeiGene; Eisai; Hengrui Pharmaceutical; Innovent Biologics; MSD; Roche; TopAlliance BioSciences Inc; Zelgen
Research Funding - Innovent Biologics (Inst); MSD (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Radiomic features to predict tumor response to systemic therapy in liver cancer patients (Inst)
 
Luna Wang
No Relationships to Disclose
 
Hanyu Jiang
No Relationships to Disclose
 
Bin Xu
No Relationships to Disclose
 
Lifang Wu
No Relationships to Disclose
 
Xueli Bai
No Relationships to Disclose
 
Tianqiang Song
No Relationships to Disclose
 
Jianqiang Cai
No Relationships to Disclose
 
Yong-Yi Zeng
No Relationships to Disclose
 
Lin Wang
No Relationships to Disclose
 
Deyu Li
No Relationships to Disclose
 
Tianfu Wen
No Relationships to Disclose
 
Yongjun Chen
No Relationships to Disclose
 
Yun Qing
No Relationships to Disclose
 
Weixia Chen
No Relationships to Disclose
 
Ziyi Wang
No Relationships to Disclose
 
Shiqi Zhou
No Relationships to Disclose
 
Ziyue Yang
No Relationships to Disclose
 
Jian Zhou
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Akeso-Sino Pharma Co., Ltd. (Inst); AstraZeneca (Inst); BeiGene (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Eddingpharm (Suzhou) Co., Ltd. (Inst); Eisai China Inc. (Inst); Fosun Pharma (Inst); Gilead Sciences (Inst); Innovent Biologics (Inst); Jiangsu Hengrui Medicine (Inst); Junshi Biosciences (Inst); MSD (Inst); OriCell Therapeutics Co.,Ltd. (Inst); Qilu Pharmaceutical (Inst); Roche (Inst); Singlera genomics (Inst); Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Inst)
 
Jia Fan
No Relationships to Disclose